A child showing a 4-day measles rash.
|Classification and external resources|
|eMedicine||derm/259 emerg/389 ped/1388|
Measles, also known as morbilli, rubeola, or red measles, is a highly contagious infection caused by the measles virus. Initial signs and symptoms typically include fever, often greater than 40 °C (104.0 °F), cough, runny nose, and red eyes. Two or three days after the start of symptoms small white spots may form inside the mouth, known as Koplik's spots. A red, flat rash which usually starts on the face and then spreads to the rest of the body typically begins three to five days after the start of symptoms. Symptoms usually develop 10–12 days after exposure to an infected person and last 7–10 days. Complications occur in about 30% and may include diarrhea, blindness, inflammation of the brain, and pneumonia among others. Rubella (German measles) and roseola are different diseases.
Measles is an airborne disease which spreads easily through the coughs and sneezes of those infected. It may also be spread through contact with saliva or nasal secretions. Nine out of ten people who are not immune who share living space with an infected person will catch it. People are infectious to others from four days before to four days after the start of the rash. People usually only get the disease at most once. Testing for the virus in suspected cases is important for public health efforts.
The measles vaccine is effective at preventing the disease. Vaccination has resulted in a 75% decrease in deaths from measles between 2000 and 2013 with about 85% of children globally being currently vaccinated. No specific treatment is available. Supportive care, however, may improve outcomes. This may include giving oral rehydration solution (slightly sweet and salty fluids), healthy food, and medications to help with the fever. Antibiotics may be used if a bacterial infection such as pneumonia occurs. Vitamin A supplementation is also recommended in the developing world.
Measles affects about 20 million people a year, primarily in the developing areas of Africa and Asia. It resulted in about 96,000 deaths in 2013 down from 545,000 deaths in 1990. In 1980, the disease is estimated to have caused 2.6 million deaths per year. Before immunization in the United States between three and four million cases occurred each year. Most of those who are infected and who die are less than five years old. The risk of death among those infected is usually 0.2%, but may be up to 10% in those who have malnutrition. It is not believed to affect other animals.
Signs and symptomsEdit
The classic signs and symptoms of measles include four-day fevers (the 4 D's) and the three C's—cough, coryza (head cold), and conjunctivitis (red eyes)—along with fever and rashes. The fever may reach up to 40 °C (104 °F). Koplik's spots seen inside the mouth are pathognomonic (diagnostic) for measles, but are temporary and therefore rarely seen. Recognizing these spots before a person reaches their maximum infectiousness can help physicians reduce the spread of the disease.
The characteristic measles rash is classically described as a generalized red maculopapular rash that begins several days after the fever starts. It starts on the back of the ears and, after a few hours, spreads to the head and neck before spreading to cover most of the body, often causing itching. The measles rash appears two to four days after the initial symptoms and lasts for up to eight days. The rash is said to "stain", changing color from red to dark brown, before disappearing.
Complications with measles are relatively common, ranging from mild complications such as diarrhea to serious complications such as pneumonia (either direct viral pneumonia or secondary bacterial pneumonia), otitis media, acute brain inflammation (and very rarely SSPE—subacute sclerosing panencephalitis), and corneal ulceration (leading to corneal scarring). Complications are usually more severe in adults who catch the virus. The death rate in the 1920s was around 30% for measles pneumonia.
Between 1987 and 2000, the case fatality rate across the United States was three measles-attributable deaths per 1000 cases, or 0.3%. In underdeveloped nations with high rates of malnutrition and poor healthcare, fatality rates have been as high as 28%. In immunocompromised persons (e.g., people with AIDS) the fatality rate is approximately 30%. Risk factors for severe measles and its complications include malnutrition, underlying immunodeficiency, pregnancy, and vitamin A deficiency.
Measles is caused by the measles virus, a single-stranded, negative-sense, enveloped RNA virus of the genus Morbillivirus within the family Paramyxoviridae. The virus was first isolated in 1954 by Nobel Laureate John F. Enders and Thomas Peebles, who were careful to point out that the isolations were made from patients who had Koplik's spots. Humans are the natural hosts of the virus; no other animal reservoirs are known to exist. This highly contagious virus is spread by coughing and sneezing via close personal contact or direct contact with secretions. Risk factors for measles virus infection include immunodeficiency caused by HIV or AIDS, leukemia, alkylating agents, or corticosteroid therapy, regardless of immunization status; travel to areas where measles is endemic or contact with travelers to endemic areas; and the loss of passive, inherited antibodies before the age of routine immunization.
Clinical diagnosis of measles requires a history of fever of at least three days, with at least one of the three C's (cough, coryza, conjunctivitis). Observation of Koplik's spots is also diagnostic of measles.
Alternatively, laboratory diagnosis of measles can be done with confirmation of positive measles IgM antibodies or isolation of measles virus RNA from respiratory specimens. For people unable to have their blood drawn, saliva can be collected for salivary measles-specific IgA testing. Positive contact with other patients known to have measles adds strong epidemiological evidence to the diagnosis. Any contact with an infected person, including semen through sex, saliva, or mucus, can cause infection.
In developed countries, children are immunized against measles at 12 months, generally as part of a three-part MMR vaccine (measles, mumps, and rubella). The vaccination is generally not given before this age because such infants respond inadequately to the vaccine due to an immature immune system. Anti-measles antibodies are transferred from mothers who have been vaccinated against measles or have been previously infected with measles to their newborn children. However, such antibodies are transferred in low amounts and usually last six months or less. Infants under one year of age whose maternal anti-measles antibodies have disappeared become susceptible to infection with the measles virus. A second dose of the vaccine is usually given to children between the ages of four and five, to increase rates of immunity. Vaccination rates have been high enough to make measles relatively uncommon. Adverse reactions to vaccination are rare, with fever and pain at the injection site being the most common. Life-threatening adverse reactions occur in less than one per million vaccinations (<0.0001%).
In developing countries where measles is highly endemic, WHO doctors recommend two doses of vaccine be given at six and nine months of age. The vaccine should be given whether the child is HIV-infected or not. The vaccine is less effective in HIV-infected infants than in the general population, but early treatment with antiretroviral drugs can increase its effectiveness. Measles vaccination programs are often used to deliver other child health interventions, as well, such as bed nets to protect against malaria, antiparasite medicine and vitamin A supplements, and so contribute to the reduction of child deaths from other causes.
There is no specific treatment for measles. Most people with uncomplicated measles will recover with rest and supportive treatment. It is, however, important to seek medical advice if the patient becomes sicker, as they may be developing complications.
Some people will develop pneumonia as a consequence of infection with the measles virus. Other complications include ear infections, bronchitis (either viral bronchitis or secondary bacterial bronchitis), and brain inflammation. Brain inflammation from measles has a mortality rate of 15%. While there is no specific treatment for brain inflammation from measles, antibiotics are required for bacterial pneumonia, sinusitis, and bronchitis that can follow measles.
All other treatment addresses symptoms, with ibuprofen or paracetamol to reduce fever and pain and, if required, a fast-acting bronchodilator for cough. As for aspirin, some research has suggested a correlation between children who take aspirin and the development of Reye syndrome. Some research has shown aspirin may not be the only medication associated with Reye, and even antiemetics have been implicated, with the point being the link between aspirin use in children and Reye syndrome development is weak at best, if not actually nonexistent. Nevertheless, most health authorities still caution against the use of aspirin for any fevers in children under 16.
The use of vitamin A during treatment is recommended by the World Health Organization to decrease the risk of blindness. A systematic review of trials into its use found no significant reduction in overall mortality, but it did reduce mortality in children aged under two years.
The majority of patients survive measles, though in some cases, complications may occur. Examples of possible consequences of measles virus infection include bronchitis, sensorineural hearing loss, and—in about 1 in 100,000 cases—panencephalitis, which is usually fatal. Acute measles encephalitis is another serious risk of measles virus infection. It typically occurs two days to one week after the breakout of the measles exanthem and begins with very high fever, severe headache, convulsions and altered mentation. A patient may become comatose, and death or brain injury may occur.
Measles is extremely infectious and its continued circulation in a community depends on the generation of susceptible hosts by birth of children. In communities which generate insufficient new hosts the disease will die out. This concept was first recognized in measles by Bartlett in 1957, who referred to the minimum number supporting measles as the critical community size (CCS). Analysis of outbreaks in island communities suggested that the CCS for measles is c. 250,000.
In 2011, the WHO estimated that there were about 158,000 deaths caused by measles. This is down from 630,000 deaths in 1990. In developed countries, death occurs in 1 to 2 cases out of every 1,000 (0.1% - 0.2%). In populations with high levels of malnutrition and a lack of adequate healthcare, mortality can be as high as 10%. In cases with complications, the rate may rise to 20–30%. In 2012, the number of deaths due to measles was 78% lower than in 2000 due to increased rates of immunization among UN member states. This reduction made up 25% of the decline in mortality in children under five during this period.
|Region of the Americas||257,790||218,579||1,755||19||3,100|
|Eastern Mediterranean Region||341,624||59,058||38,592||15,069||2,214|
|South-East Asia Region||199,535||224,925||61,975||83,627||1,540|
|Western Pacific Region||1,319,640||155,490||176,493||128,016||34,310|
Even in countries where vaccination has been introduced, rates may remain high. In Ireland, vaccination was introduced in 1985. There were 99,903 cases that year. Within two years, the number of cases had fallen to 201, but this fall was not sustained. Measles is a leading cause of vaccine-preventable childhood mortality. Worldwide, the fatality rate has been significantly reduced by a vaccination campaign led by partners in the Measles Initiative: the American Red Cross, the United States' Centers for Disease Control and Prevention (CDC), the United Nations Foundation, UNICEF and the WHO. Globally, measles fell 60% from an estimated 873,000 deaths in 1999 to 345,000 in 2005. Estimates for 2008 indicate deaths fell further to 164,000 globally, with 77% of the remaining measles deaths in 2008 occurring within the Southeast Asian region.
In 2006–07 there were 12,132 cases in 32 European countries: 85% occurred in five countries: Germany, Italy, Romania, Switzerland and the UK. 80% occurred in children and there were 7 deaths.
Five out of six WHO regions have set goals to eliminate measles, and at the 63rd World Health Assembly in May 2010, delegates agreed a global target of a 95% reduction in measles mortality by 2015 from the level seen in 2000, as well as to move towards eventual eradication. However, no specific global target date for eradication has yet been agreed to as of May 2010.
The Antonine Plague, 165–180 AD, also known as the Plague of Galen, who described it, was probably smallpox or measles. The epidemic may have claimed the life of Roman emperor Lucius Verus. Total deaths have been estimated at five million. Estimates of the timing of evolution of measles seem to suggest this plague was something other than measles. The first scientific description of measles and its distinction from smallpox and chickenpox is credited to the Persian physician Rhazes (860–932), who published The Book of Smallpox and Measles. Given what is now known about the evolution of measles, this account is remarkably timely, as recent work that examined the mutation rate of the virus indicates the measles virus emerged from rinderpest (Cattle Plague) as a zoonotic disease between 1100 and 1200 AD, a period that may have been preceded by limited outbreaks involving a virus not yet fully acclimated to humans. This agrees with the observation that measles requires a susceptible population of >500,000 to sustain an epidemic, a situation that occurred in historic times following the growth of medieval European cities.
Measles is an endemic disease, meaning it has been continually present in a community, and many people develop resistance. In populations not exposed to measles, exposure to the new disease can be devastating. In 1529, a measles outbreak in Cuba killed two-thirds of the natives who had previously survived smallpox. Two years later, measles was responsible for the deaths of half the population of Honduras, and had ravaged Mexico, Central America, and the Inca civilization.
Between roughly 1855 and 2005, measles has been estimated to have killed about 200 million people worldwide. Measles killed 20 percent of Hawaii's population in the 1850s. In 1875, measles killed over 40,000 Fijians, approximately one-third of the population. In the 19th century, the disease killed 50% of the Andamanese population.
In 1954, the virus causing the disease was isolated from a 13-year-old boy from the United States, David Edmonston, and adapted and propagated on chick embryo tissue culture. To date, 21 strains of the measles virus have been identified. While at Merck, Maurice Hilleman developed the first successful vaccine. Licensed vaccines to prevent the disease became available in 1963. An improved measles vaccine became available in 1968.
- Caserta, MT, ed. (September 2013). "Measles". Merck Manual Professional. Merck Sharp & Dohme Corp. Retrieved 23 March 2014.
- "Measles (Red Measles, Rubeola)". http://www.health.gov.sk.ca/. Retrieved 10 February 2015.
- "Measles (Rubeola) Signs and Symptoms". cdc.gov. November 3, 2014. Retrieved 5 February 2015.
- "Measles Fact sheet N°286". who.int. November 2014. Retrieved 4 February 2015.
- Conn's Current Therapy 2015: Expert Consult - Online. Elsevier Health Sciences. 2014. p. 153. ISBN 9780323319560.
- Atkinson, William (2011). Epidemiology and Prevention of Vaccine-Preventable Diseases (12 ed.). Public Health Foundation. pp. 301–323. ISBN 9780983263135. Retrieved 5 February 2015.
- Marx, John A. (2010). Rosen's emergency medicine : concepts and clinical practice (7th ed. ed.). Philadelphia: Mosby/Elsevier. p. 1541. ISBN 9780323054720.
- GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet. doi:10.1016/S0140-6736(14)61682-2. PMID 25530442.
- Baxby D (1997). "Classic Paper: Henry Koplik. The diagnosis of the invasion of measles from a study of the exanthema as it appears on the buccal membrane". Reviews in Medical Virology 7 (2): 71–4. doi:10.1002/(SICI)1099-1654(199707)7:2<71::AID-RMV185>3.0.CO;2-S. PMID 10398471.
- NHS UK: Symptoms of measles. Last reviewed: 26/01/2010.
- Yasunaga H, Shi Y, Takeuchi M, Horiguchi H, Hashimoto H, Matsuda S, Ohe K (2010). "Measles-related hospitalizations and complications in Japan, 2007-2008". Internal Medicine (Tokyo, Japan) 49 (18): 1965–1970. doi:10.2169/internalmedicine.49.3843. PMID 20847499.
- Gardiner, W. T. (2007). "Otitis Media in Measles". The Journal of Laryngology & Otology 39 (11): 614. doi:10.1017/S0022215100026712.
- Fisher DL, Defres S, Solomon T (2014). "Measles-induced encephalitis". QJM. Epub ahead of print. doi:10.1093/qjmed/hcu113. PMID 24865261. Retrieved August 27, 2014.
- Anlar B (2013). "Subacute sclerosing panencephalitis and chronic viral encephalitis". Handbook of Clinical Neurology 112: 1183–1189. doi:10.1016/B978-0-444-52910-7.00039-8. PMID 23622327.
- Foster A, Sommer A (1987). "Corneal ulceration, measles, and childhood blindness in Tanzania". The British Journal of Ophthalmology 71 (5): 331–343. doi:10.1136/bjo.71.5.331. PMC 1041162. PMID 3580349.
- Sabella C (2010). "Measles: Not just a childhood rash". Cleveland Clinic Journal of Medicine 77 (3): 207–213. doi:10.3949/ccjm.77a.09123. PMID 20200172.
- Ellison, J.B (1931). "Pneumonia in Measles". 1931 Archives of Disease in Childhood 6 (31). pp. 37–52. PMC 1975146.
- Perry RT, Halsey NA (May 1, 2004). "The Clinical Significance of Measles: A Review". The Journal of Infectious Diseases 189 (S1): S4–16. doi:10.1086/377712. PMID 15106083.
- Sension MG, Quinn TC, Markowitz LE, Linnan MJ, Jones TS, Francis HL, Nzilambi N, Duma MN, Ryder RW (1988). "Measles in hospitalized African children with human immunodeficiency virus". American Journal of Diseases of Children (1960) 142 (12): 1271–2. doi:10.1001/archpedi.1988.02150120025021. PMID 3195521.
- Chen S.S.P. (October 3, 2011). Measles (Report). Medscape.
- Polonsky JA, Ronsse A, Ciglenecki I, Rull M, Porten K (2013). "High levels of mortality, malnutrition, and measles, among recently-displaced Somali refugees in Dagahaley camp, Dadaab refugee camp complex, Kenya, 2011". Conflict and Health 7 (1): 1. doi:10.1186/1752-1505-7-1. PMC 3607918. PMID 23339463.
- Kanda E, Yamaguchi K, Hanaoka M, Matsui H, Sago H, Kubo T (2013). "Low titers of measles antibodies in Japanese pregnant women: A single-center study". The Journal of Obstetrics and Gynaecology Research 39 (2): 500–503. doi:10.1111/j.1447-0756.2012.01997.x. PMID 22925573.
- "Vitamin A".
- Cohen BE, Durstenfeld A, Roehm PC (July 2014). "Viral causes of hearing loss: a review for hearing health professionals". Trends in Hearing 18: 2331216514541361. doi:10.1177/2331216514541361. PMC 4222184. PMID 25080364.
- Enders JF, Peebles TC (1954). "Propagation in tissue culture of cytopathogenic agents from patients with measles". Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 86 (2): 277–86. doi:10.3181/00379727-86-21073. PMID 13177653.
- Gowda VK, Sukanya V (2012). "Acquired Immunodeficiency Syndrome with Subacute Sclerosing Panencephalitis". Pediatric Neurology 47 (5): 379–381. doi:10.1016/j.pediatrneurol.2012.06.020. PMID 23044024.
- Breitfeld V, Hashida Y, Sherman FE, Odagiri K, Yunis EJ (1973). "Fatal measles infection in children with leukemia". Laboratory Investigation; A Journal of Technical Methods and Pathology 28 (3): 279–291. PMID 4348408.
- Leuridan E, Sabbe M, Van Damme P (September 2012). "Measles outbreak in Europe: susceptibility of infants too young to be immunized". Vaccine 30 (41): 5905–13. doi:10.1016/j.vaccine.2012.07.035. PMID 22841972.
- Total Health (May 5, 2010). "Actual Confirmed Measles Cases in UK". totalhealth. Retrieved May 4, 2013.
- Helfand RF, Heath JL, Anderson LJ, Maes EF, Guris D, Bellini WJ (1997). "Diagnosis of measles with an IgM capture EIA: The optimal timing of specimen collection after rash onset". The Journal of Infectious Diseases 175 (1): 195–199. doi:10.1093/infdis/175.1.195. PMID 8985220.
- Njayou M, Balla A, Kapo E (1991). "Comparison of four techniques of measles diagnosis: Virus isolation, immunofluorescence, immunoperoxidase & ELISA". The Indian Journal of Medical Research 93: 340–344. PMID 1797639.
- Friedman M, Hadari I, Goldstein V, Sarov I (1983). "Virus-specific secretory IgA antibodies as a means of rapid diagnosis of measles and mumps infection". Israel Journal of Medical Sciences 19 (10): 881–884. PMID 6662670.
- Galindo BM, Concepción D, Galindo MA, Pérez A, Saiz J (2012). "Vaccine-related adverse events in Cuban children, 1999–2008". MEDICC Review 14 (1): 38–43. PMID 22334111.
- Helfand RF, Witte D, Fowlkes A, Garcia P, Yang C, Fudzulani R, Walls L, Bae S, Strebel P, Broadhead R, Bellini WJ, Cutts F (2008). "Evaluation of the immune response to a 2-dose measles vaccination schedule administered at 6 and 9 months of age to HIV-infected and HIV-uninfected children in Malawi". The Journal of Infectious Diseases 198 (10): 1457–65. doi:10.1086/592756. PMID 18828743.
- Ołdakowska A, Marczyńska M (2008). "Measles vaccination in HIV infected children". Medycyna Wieku Rozwojowego 12 (2 Pt 2): 675–680. PMID 19418943.
- UNICEF Joint Press Release
- "Complications of Measles". Centers for Disease Control and Prevention (CDC).
- Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall DF (6 Dec 1980). "Reye's Syndrome and Salicylate Use". Pediatrics 66 (6): 859–64. PMID 7454476. Retrieved 2011-03-17.
It is postulated that salicylate [taken by school-age children], operating in a dose-dependent manner, possibly potentiated by fever, represents a primary causative agent of Reye's syndrome.
- Casteels-Van Daele M, Van Geet C, Wouters C, Eggermont E (April 2000). "Reye syndrome revisited: a descriptive term covering a group of heterogeneous disorders". European Journal of Pediatrics 159 (9): 641–8. doi:10.1007/PL00008399. PMID 11014461. Retrieved 2011-03-17.
Reye syndrome is a non-specific descriptive term covering a group of heterogeneous disorders. Moreover, not only the use of acetylsalicylic acid but also of antiemetics is statistically significant in Reye syndrome cases. Both facts weaken the validity of the epidemiological surveys suggesting a link with acetylsalicylic acid.
- Schrör K (2007). "Aspirin and Reye Syndrome: A Review of the Evidence". Paediatric Drugs 9 (3): 195–204. doi:10.2165/00148581-200709030-00008. PMID 17523700. Retrieved 2011-03-17.
The suggestion of a defined cause-effect relationship between aspirin intake and Reye syndrome in children is not supported by sufficient facts. Clearly, no drug treatment is without side effects. Thus, a balanced view of whether treatment with a certain drug is justified in terms of the benefit/risk ratio is always necessary. Aspirin is no exception.
- Macdonald S (2002). "Aspirin use to be banned in under 16 year olds". BMJ (Clinical Research Ed.) 325 (7371): 988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585. PMID 12411346.
Professor Alasdair Breckenridge, said, "There are plenty of analgesic products containing paracetamol and ibuprofen for this age group not associated with Reye's syndrome. There is simply no need to expose those under 16 to the risk—however small."
- "Aspirin and Reye's Syndrome". MHRA. October 2003. Retrieved 2011-03-17.
- "Surgeon General's advisory on the use of salicylates and Reye syndrome". MMWR. Morbidity and Mortality Weekly Report 31 (22): 289–90. June 1982. PMID 6810083.
- Reye's Syndrome at NINDS "Epidemiologic evidence indicates that aspirin (salicylate) is the major preventable risk factor for Reye's syndrome. The mechanism by which aspirin and other salicylates trigger Reye's syndrome is not completely understood."
- "Measles vaccines: WHO position paper.". Weekly epidemiological record 84 (35): 349-60. 28 August 2009. PMID 19714924.
- Huiming Y, Chaomin W, Meng M (2005). Yang, Huiming, ed. "Vitamin A for treating measles in children". The Cochrane Database of Systematic Reviews (4): CD001479. doi:10.1002/14651858.CD001479.pub3. PMID 16235283.
- D'Souza RM, D'Souza R (2002). "Vitamin A for treating measles in children". The Cochrane Database of Systematic Reviews (1): CD001479. doi:10.1002/14651858.CD001479. PMID 11869601.
- D'Souza RM, D'Souza R (April 2002). "Vitamin A for preventing secondary infections in children with measles—a systematic review". Journal of Tropical Pediatrics 48 (2): 72–7. doi:10.1093/tropej/48.2.72. PMID 12022432.
-  "Sub acute sclerosing panencephalitis"
-  "NINDS Subacute Sclerosing Panencephalitis Information Page"
- 14-193b. at Merck Manual of Diagnosis and Therapy Professional Edition
- Bartlett, M.S. (1957). "Measles periodicity and community size". J. Roy. Stat. Soc. Ser. A (120): 48–70.
- Black FL (1966). "Measles endemicity in insular populations; critical community size and its evolutionary implications". Journal of Theoretical Biology 11 (2): 207–11. doi:10.1016/0022-5193(66)90161-5. PMID 5965486.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. (Dec 15, 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
- "Complications of measles". CDC. November 3, 2014. Retrieved November 7, 2014.
- Measles, World Health Organization Fact sheet N°286. Retrieved June 28, 2012. Updated February 2014
- "Millennium Development Goals Reports". United Nations. Retrieved 18 March 2013.
- "Millennium Development Goals (MDGs), Fact Sheet N°290". WHO. May 2014. Retrieved November 7, 2014.
- WHO: Global summary on measles, 2006
- Measles Surveillance Data after WHO, last updated 2014-3-6
- Measles reported cases by WHO in 2014
- Số người chết và mắc bệnh theo quốc gia, last update 2014-4-7 by WHO
- WHO Weekly Epidemiology Record, 4th December 2009 WHO.int
- McNeil, G.C. (January 12, 2009). "Eradication Goal for Measles Is Unlikely, Report Says". New York Times. Retrieved May 3, 2013.
- "Sixty-third World Health Assembly Agenda provisional agenda item 11.15 Global eradication of measles". Retrieved 2 June 2010.
- "Sixty-third World Health Assembly notes from day four". Retrieved 2 June 2010.
- Plague in the Ancient World
- "Past pandemics that ravaged Europe", BBC News, November 7, 2005
- Harminder S. Dua, Ahmad Muneer Otri, Arun D. Singh (2008). "Abu Bakr Razi". British Journal of Ophthalmology (BMJ Group) 92: 1324.
- Furuse, Yuki; Akira Suzuki; Hitoshi Oshitani (2010-03-04). "Origin of measles virus: divergence from rinderpest virus between the 11th and 12th centuries". Virology Journal 7: 52. doi:10.1186/1743-422X-7-52. ISSN 1743-422X. PMC 2838858. PMID 20202190. Retrieved 2014-09-14.
- Black, Francis L. (July 1966). "Measles endemicity in insular populations: Critical community size and its evolutionary implication". Journal of Theoretical Biology 11 (2): 207–211. doi:10.1016/0022-5193(66)90161-5. ISSN 0022-5193. PMID 5965486. Retrieved 2014-10-15.
- "Maurice R. Hilleman Dies; Created Vaccines". The Washington Post. April 13, 2005.
- Byrne, Joseph Patrick (2008). Encyclopedia of Pestilence, Pandemics, and Plagues: A–M. ABC-CLIO. p. 413. ISBN 0-313-34102-8.
- Torrey EF and Yolken RH. 2005. Their bugs are worse than their bite. Washington Post, April 3, p. B01.
- Migration and Disease. Digital History.
- Fiji School of Medicine
- Measles hits rare Andaman tribe. BBC News. May 16, 2006.
- "Live attenuated measles vaccine". EPI Newsletter / C Expanded Program on Immunization in the Americas 2 (1): 6. 1980. PMID 12314356.
- Rima BK, Earle JA, Yeo RP, Herlihy L, Baczko K, ter Meulen V, Carabaña J, Caballero M, Celma ML, Fernandez-Muñoz R (1995). "Temporal and geographical distribution of measles virus genotypes". The Journal of General Virology 76 (5): 1173–80. doi:10.1099/0022-1317-76-5-1173. PMID 7730801.
- Offit PA (2007). Vaccinated: One Man's Quest to Defeat the World's Deadliest Diseases. Washington, DC: Smithsonian. ISBN 0-06-122796-X.
- "Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP)". Centers for Disease Control and Prevention (CDC).
- Measles: Questions and Answers, Immunization Action Coalition.
- White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK (2007). "Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity". Antimicrobial Agents and Chemotherapy 51 (7): 2293–303. doi:10.1128/AAC.00289-07. PMC 1913224. PMID 17470652.
- Krumm SA, Yan D, Hovingh ES, Evers TJ, Enkirch T, Reddy GP, Sun A, Saindane MT, Arrendale RF, Painter G, Liotta DC, Natchus MG, von Messling V, Plemper RK (2014). "An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model". Science Translational Medicine 6 (232): 232ra52. doi:10.1126/scitranslmed.3008517. PMID 24739760.
- Will an anti-viral drug put paid to measles? New Scientist 16 April 2014
|Wikimedia Commons has media related to Measles.|
- WHO.int—'Initiative for Vaccine Research (IVR): Measles', World Health Organization (WHO)
- Measles FAQ from Centers for Disease Control and Prevention in the United States
- Case of an adult male with measles (facial photo)
- Clinical pictures of measles
- Virus Pathogen Database and Analysis Resource (ViPR): Paramyxoviridae